Gabriela Andrejeva

Gabriela Andrejeva

Auto-generated profile, based on publicly available information

Gabriela Andrejeva

Center for Immunobiology, Vanderbilt University Medical Center, Nashville, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Cell
Verified
Journal Article
Closed access
MJMarc O. Johnson
Marc O. Johnson
MWMelissa M. Wolf
Melissa M. Wolf
MMMatthew Z. Madden
Matthew Z. Madden
GAGabriela Andrejeva
Gabriela Andrejeva
ASAyaka Sugiura
Ayaka Sugiura
JRJeffrey C. Rathmell
Jeffrey C. Rathmell

1 October 2017 in Cell Metabolism
Verified
Journal Article
Closed access
KLKyung-min Lee
Kyung-min Lee
JGJennifer M. Giltnane
Jennifer M. Giltnane
JBJustin M. Balko
Justin M. Balko
LSLuis J. Schwarz
Luis J. Schwarz
AGAngel L. Guerrero-Zotano
Angel L. Guerrero-Zotano
CACarlos L. Arteaga
Carlos L. Arteaga

15 June 2017 in JCI Insight
Verified
Journal Article
Open access
PDF file
PSPeter J. Siska
Peter J. Siska
KBKathryn E. Beckermann
Kathryn E. Beckermann
FMFrank M. Mason
Frank M. Mason
GAGabriela Andrejeva
Gabriela Andrejeva
AGAllison R. Greenplate
Allison R. Greenplate
JRJeffrey C. Rathmell
Jeffrey C. Rathmell
Cancer cells can inhibit effector T cells (Teff) through both immunomodulatory receptors and the impact of cancer metabolism on the tumor microenvironment. Indeed, Teff require high rates of glucose metabolism, and consumption of essential nutrients or generation of waste products by tumor cells may impede essential T cell metabolic pathways. Clear cell renal cell carcinoma (ccRCC) is characterized by loss of the tumor suppressor von Hippel-Lindau ( VHL ) and altered cancer cell metabolism. Here, we assessed how ccRCC influences the metabolism and activation of primary patient ccRCC tumor infiltrating lymphocytes (TIL). CD8 TIL were abundant in ccRCC, but they were phenotypically distinct and both functionally and metabolically impaired. ccRCC CD8 TIL were unable to efficiently uptake glucose or perform glycolysis and had small, fragmented mitochondria that were hyperpolarized and generated large amounts of ROS. Elevated ROS was associated with downregulated mitochondrial SOD2. CD8 T cells with hyperpolarized mitochondria were also visible in the blood of ccRCC patients. Importantly, provision of pyruvate to bypass glycolytic defects or scavengers to neutralize mitochondrial ROS could partially restore TIL activation. Thus, strategies to improve metabolic function of ccRCC CD8 TIL may promote the immune response to ccRCC.

1 July 2017 in Cell Metabolism
Verified
Journal Article
Closed access
GAGabriela Andrejeva
Gabriela Andrejeva
JRJeffrey C. Rathmell
Jeffrey C. Rathmell

11 November 2021 in Immunity
Verified
Journal Article
Closed access
ASAyaka Sugiura
Ayaka Sugiura
GAGabriela Andrejeva
Gabriela Andrejeva
KVKelsey Voss
Kelsey Voss
DHDarren R. Heintzman
Darren R. Heintzman
XXXincheng Xu
Xincheng Xu
JRJeffrey C. Rathmell
Jeffrey C. Rathmell

13 September 2019 in Autophagy
Verified
Journal Article
Open access
GAGabriela Andrejeva
Gabriela Andrejeva
SGSharon Gowan
Sharon Gowan
Gigin LinGigin Lin
Gigin Lin
AFAnne-Christine Lf Wong Te Fong
Anne-Christine Lf Wong Te Fong
ESElham Shamsaei
Elham Shamsaei
YCYuen-Li Chung
Yuen-Li Chung
Macroautophagy/autophagy can enable cancer cells to withstand cellular stress and maintain bioenergetic homeostasis by sequestering cellular components into newly formed double-membrane vesicles destined for lysosomal degradation, potentially affecting the efficacy of anti-cancer treatments. Using 13C-labeled choline and 13C-magnetic resonance spectroscopy and western blotting, we show increased de novo choline phospholipid (ChoPL) production and activation of PCYT1A (phosphate cytidylyltransferase 1, choline, alpha), the rate-limiting enzyme of phosphatidylcholine (PtdCho) synthesis, during autophagy. We also discovered that the loss of PCYT1A activity results in compromised autophagosome formation and maintenance in autophagic cells. Direct tracing of ChoPLs with fluorescence and immunogold labeling imaging revealed the incorporation of newly synthesized ChoPLs into autophagosomal membranes, endoplasmic reticulum (ER) and mitochondria during anticancer drug-induced autophagy. Significant increase in the colocalization of fluorescence signals from the newly synthesized ChoPLs and mCherry-MAP1LC3/LC3 (microtubule-associated protein 1 light chain 3) was also found on autophagosomes accumulating in cells treated with autophagy-modulating compounds. Interestingly, cells undergoing active autophagy had an altered ChoPL profile, with longer and more unsaturated fatty acid/alcohol chains detected. Our data suggest that de novo synthesis may be required to increase autophagosomal ChoPL content and alter its composition, together with replacing phospholipids consumed from other organelles during autophagosome formation and turnover. This addiction to de novo ChoPL synthesis and the critical role of PCYT1A may lead to development of agents targeting autophagy-induced drug resistance. In addition, fluorescence imaging of choline phospholipids could provide a useful way to visualize autophagosomes in cells and tissues. Abbreviations: AKT: AKT serine/threonine kinase; BAX: BCL2 associated X, apoptosis regulator; BECN1: beclin 1; ChoPL: choline phospholipid; CHKA: choline kinase alpha; CHPT1: choline phosphotransferase 1; CTCF: corrected total cell fluorescence; CTP: cytidine-5ʹ-triphosphate; DCA: dichloroacetate; DMEM: dulbeccos modified Eagles medium; DMSO: dimethyl sulfoxide; EDTA: ethylenediaminetetraacetic acid; ER: endoplasmic reticulum; GDPD5: glycerophosphodiester phosphodiesterase domain containing 5; GFP: green fluorescent protein; GPC: glycerophosphorylcholine; HBSS: hanks balances salt solution; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; LPCAT1: lysophosphatidylcholine acyltransferase 1; LysoPtdCho: lysophosphatidylcholine; MRS: magnetic resonance spectroscopy; MTORC1: mechanistic target of rapamycin kinase complex 1; PCho: phosphocholine; PCYT: choline phosphate cytidylyltransferase; PLA2: phospholipase A2; PLB: phospholipase B; PLC: phospholipase C; PLD: phospholipase D; PCYT1A: phosphate cytidylyltransferase 1, choline, alpha; PI3K: phosphoinositide-3-kinase; pMAFs: pancreatic mouse adult fibroblasts; PNPLA6: patatin like phospholipase domain containing 6; Pro-Cho: propargylcholine; Pro-ChoPLs: propargylcholine phospholipids; PtdCho: phosphatidylcholine; PtdEth: phosphatidylethanolamine; PtdIns3P: phosphatidylinositol-3-phosphate; RPS6: ribosomal protein S6; SCD: stearoyl-CoA desaturase; SEM: standard error of the mean; SM: sphingomyelin; SMPD1/SMase: sphingomyelin phosphodiesterase 1, acid lysosomal; SGMS: sphingomyelin synthase; WT: wild-type